LC

Laia Crespo

Partner - Sanofi Ventures

Paris, Île-de-France

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $7,500,000.00

Education

Investments

Eligo Bioscience

Series B

Total Funding: $48M

QurAlis

Series B

Total Funding: $140M

OMass Therapeutics

Series B

Total Funding: $95M

Lava Therapeutics

Series C

Total Funding: $100M

Inbiomotion

Series A

Total Funding: $4M

Minoryx Therapeutics

Series A

Total Funding: $81M

AM Pharma

Series D

Total Funding: $210M

Work Experience

S
Sanofi

2018

  • Partner - Sanofi Ventures

    2018

    Current board member in Eligo Bioscience, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, T-Therapeutics and Therini Bio. Previous investor / board member in Lava Therapeutics (LVTX)

YC
Ysios Capital

2009 - 2018

  • Investment Director

    2015 - 2018

    Board Member in Minoryx, OxThera

  • Investment Manager

    2009 - 2015

    Board member in AM-Pharma, Inbiomotion

J&
Johnson & Johnson

2008 - 2009

  • New Business Development Analyst for Europe, Middle East and Africa

    2008 - 2009

U
UCB

2007 - 2007

  • Research Scientist

    2007 - 2007

MA
Medivir AB

2004 - 2007

  • Research Scientist

    2004 - 2007

Spirogen (now AstraZeneca)

2002 - 2003

  • Research Scientist

    2002 - 2003